Background Infantile hemangioma (
Introduction
Infantile hemangioma (IH) is the most common benign tumor of infancy, but its pathogenesis and the mechanisms regulating its natural history are not well understood. IHs are known to go through rapid proliferation in the early neonatal period, followed by involution [1, 2] . Many studies have characterized and analyzed IH tissues. IHs were first distinguished from other vascular malformations by clinical history and histological characteristics [3] . The seminal paper by North et al. demonstrated that endothelial cells in IH stain positive for the glucose transporter-1 (GLUT1). GLUT1 is specifically expressed in IH as it is not found in other types of vascular tumors nor in vascular malformations; it is currently the gold standard for histological diagnosis of IH [4] . However, it is not known what the functional significance of GLUT-1 may be in the pathogenesis of IH. More recently, several studies have pointed to the molecular similarities between placenta and IH [5] [6] [7] that are not shared by other vascular tumors.
Other studies have documented differences in gene and protein expression between proliferating and involuting hemangiomas [8] [9] [10] [11] [12] . Proliferating and involuting hemangioma tissues have been analyzed by a variety of methods, including histopathological analyses, RT-PCR, and microarray analyses, for differences in gene expression between the proliferating and involuting phases to identify potential regulators or mediators of hemangiogenesis. Some genes have been shown to have differential expression between proliferating and involuting hemangiomas: two examples are insulin-like growth factor 2 (IFG-2) [11] and indoleamine 2,3-dioxygenase (IDO) [10] . However, potential mechanisms on how these factors could regulate the phases of hemangioma have not been elucidated.
More recently, using laser capture microdissection and genome-wide transcriptional profiling, a list of genes expressed in the endothelial-lined vessels of hemangiomas in the proliferating and involuting phases was compiled and compared to gene expression in placental vessels. Cellular proliferation genes, such as Ki67, were found to be highly expressed in proliferating hemangiomas, whereas chronic inflammatory mediators, such as clusterin, were highly expressed in involuting hemangiomas [12] . Pertinent to this study, Jagged-1 and Notch4 were found to be increased 6.5-fold and 3.2-fold, respectively, in proliferating IH vessels compared to placental vessels [12] .
There has been a steady debate as to whether intrinsic or extrinsic factors drive the pathogenesis of IH. The intrinsic theory of hemangioma origin postulates that the defect resides within cells of IH, in contrast to the extrinsic theory, which postulates that the surrounding environment contributes to the pathogenesis of IH [13] . Evidence that support the intrinsic theory includes studies that demonstrated that HemECs showed clonality, suggesting an intrinsic defect leading to formation of the lesion [14, 15] . Moreover, HemECs were shown to have altered expression of the angiogenic regulator Tie2 [16] . An imbalance between VEGFR1 and VEGFR2 signaling in HemECs has also been uncovered, which may contribute to the pathogenesis of hemangioma [17] . Evidence for endothelial progenitor cells (HemEPCs) in IH was first reported based on simultaneous expression of endothelial and progenitor cell markers [18] . Circulating endothelial progenitor cells were also reported in the blood samples from patients with IHs [19] . Both HemEPCs and HemECs showed properties of immature endothelial cell phenotype and behavior [20] . More recently, hemangioma-derived stem cells (HemSCs) have been isolated from proliferating IH and shown to differentiate into multiple lineages. Moreover, HemSCs implanted into nude mice differentiated into GLUT1-positive endothelial cells that had assembled into perfused blood vessels. To date, this is the first in vivo model that recapitulates, at least partially, the unique features of IH. Based on the in vitro multipotentiality and in vivo model, the HemSC may be the cell of origin of IH [21] .
Notch signaling has been shown to play a role in cell fate determination and arterial endothelial specification during embryogenesis [22] [23] [24] . In addition, Notch signaling also plays a role in postnatal tumor angiogenesis [25, 26] and is an anti-angiogenic therapeutic target. Inhibition of delta-like ligand 4 (Dll4) signaling led to the inhibition of tumor angiogenesis [27] . In addition, inhibition of the Notch signaling pathway has been shown to inhibit tumor angiogenesis in a mouse model [28] . Moreover, Notch proteins may exert their effects on vasculogenesis and angiogenesis via VEGFR signaling [29, 30] . Therefore, Notch may play a role in the pathogenesis of IHs via the VEGFR pathways. Preliminary studies by RT-PCR showed that Notch genes are expressed in hemangiomas [31] . This study will further investigate the expression of Notch receptors and ligands in hemangiomas.
Materials and methods
Preparation of hemangioma specimen IRB approval for the collection of hemangiomas and control tissues were obtained from Columbia University College of Physicians and Surgeons (IRB #AAAA9976). Skin and placenta were chosen as control tissues. Skin was chosen as control, as resected IHs were cutaneous in origin; placenta was chosen based on the hypothesis of a placental origin of hemangiomas [6] . Tissues were either fixed in formalin or stored in RNAlater (Qiagen) and stored at -80°C until use.
RNA isolation and RT-PCR
Total RNA isolation was performed with RNeasy Mini Prep Kit (Qiagen). Quality of RNA was determined with spectrophotometry for optical density at 260/280 nm. cDNA was synthesized by reverse transcription of 1-2 lg of total RNA, performed using the Superscript II system (Invitrogen). All reverse transcription (RT) reactions were probed for the expression of the reporter gene b-actin to confirm successful generation of cDNA.
Real-time PCR
Real-time PCR was performed with the Applied Biosystem 7300 and Syber Green Master Mix (Applied Biosystems) and done in triplicates. The PCR mixture consisted of Syber Green Master Mix, forward and reverse primers, and H 2 O. The reaction mixture consisted of 57 ll of PCR mixture and 4.5 ll of cDNA, or 3 ll of real-time standards and 1.5 ll H 2 O. Realtime standards were provided by Carrie Shawber (Columbia University). The PCR was performed for 40 cycles with the following temperature cycles: 50°C (2 min) followed by 95°C (2 min) for initiation, followed by 40 cycles at 95 (15 s), 60 (40 s), and 72 (30 s). The results are normalized to b-actin levels and the triplicate results averaged for each sample.
Primer sequence
0 CTC GTA GAT GGG CAC AGT GTG 3 0 .
HemSC and HemEC
RNA from isolated HemSC and HemECs from two patients (Hem131 and Hem133) was provided by EB and JB and prepared according to previously published protocols [20, 21] . cDNA synthesis and real-time PCR were performed with the same protocol as for hemangioma whole tissue. RNA from human dermal microvascular endothelial cells (HDMEC) was used as control. In addition, mesenchymal stem cells (MSC) were used as control RNA as well.
Immunofluorescence and double staining
Immunofluorescence was performed for Notch3 staining, as well as for co-staining Notch receptors with CD31, a marker of endothelial cells. Briefly, the slides were deparaffinized, and avidin and biotin were added with the blocking agents. The blocking agent was blotted off, and the first antibody was added to incubate overnight at 4°C. The slides were washed and incubated with the second antibody at room temperature for 30 min. Slides were incubated with immunofluorescent dye: Alexa fluor 488 (green) and 594 (red). Vectashield with DAPI (Vector) was applied to the slides, and coverslip was placed, and the slides were kept in dark. The antibodies used were: Notch3 (Abcam 23426, dilution 1:50) with second antibody (goat anti-rabbit, dilution 1:500), Notch1 (Abcam 17843, prediluted; secondary antibody horse anti-mouse, dilution 1:200), Notch4 (Santa Cruz H225, dilution 1:100; secondary antibody goat anti-rabbit, dilution 1:500), Jagged-1 (R&D AF1277, dilution 1:200; secondary antibody rabbit anti-goat, dilution 1:300), and CD31 (Dako, M0823, dilution 1:20; secondary antibody horse anti-mouse, dilution 1:300). All secondary antibodies were from Vector Laboratories.
Statistical analysis
For qPCR results, levels were measured in triplicate and normalized to b-actin for an assigned value and standard deviation. Statistical significance in the difference between two samples was calculated using Student's t-test. A P value of 0.05 or less was considered statistically significant.
Results

Notch gene expression pattern in IHs is unique
We compared Notch expression pattern in IH, placenta, and skin. Skin was chosen as most IHs are cutaneous-that is, in the epidermis and dermis. Previous studies have indicated molecular similarities between placenta and IH, lending support to the idea of a placental origin for IH [7] . Therefore, placenta was chosen as a tissue for comparison with IH. All four Notch receptors Notch1-4, as well as two endothelial-associated ligands, Jagged-1, and Delta-like ligand 4 (Dll4), were studied.
Hemangioma
Both proliferating and involuting IH expressed Notch1, Notch3, Notch4, Jagged-1, and Dll4 mRNA. All transcript levels were higher than placenta. In addition, relative expression levels of Notch4 and Jagged-1 were higher in involuting hemangiomas when compared to proliferating hemangiomas. Notch1 and Notch3 expressions were comparable to skin, but the Notch4, Jagged-1, and Dll4 had higher levels when compared to skin. However, the transcript levels of Notch2 were lower in hemangiomas compared to both placenta and skin (Fig. 1) .
Placenta
The endothelial-specific Notch genes had low expression levels compared to IH. Notch2 expression levels were higher in placenta. In summary, the expression pattern in placenta was distinct from hemangiomas.
Skin
Skin had comparable levels of Notch1 and Notch3 expressions to hemangiomas, but had relatively low levels of other endothelial-specific Notch genes (Notch4, Jagged-1, and Dll4). Similar to placenta, skin had high levels of Notch2 expression.
Notch expression in isolated HemSCs and HemECs in IH
Isolated HemSC and HemECs
In addition to whole tissue analyses, cells isolated from IHs-HemSCs and HemECs-were analyzed with the hypothesis that the changes seen between proliferating and involuting IH might be reflected in the isolated cell populations. HemSC and HemECs isolated from hemangiomas in two patients (Hem131 and Hem133) were used. HemSCs are multipotential stem cells that were shown to differentiate into endothelial cells and adipocytes. They were isolated initially by immunoselection using anti-CD133-coated magnetic beads and expanded in culture. HemSCs express the mesenchymal marker CD90 but not endothelial or hematopoietic markers. HemECs, on the other hand, are VE-cadherin and PECAM-1/CD31-positive endothelial cells from proliferating hemangioma that share in vitro characteristics with immature endothelial cells [20] .
Notch3 is expressed in IH-derived stem cells (HemSC)
Isolated HemSCs had increased levels of expression of Notch3 when compared to the differentiated HemEC; (42-130-fold increase). Notch3 levels in HemSCs were also higher than human microvascular endothelial cells (HDMEC; 200-1,300-fold), where levels were almost undetectable. Notch3 expression in HemSC was comparable to mesenchymal stem cells (MSC; 0.4-2.6-fold; data not shown) (Fig. 2) .
Notch2 was also highly expressed in HemSCs when compared to HemECs and HDMECs, parallel to Notch3 expression, further supporting the distinct phenotype of HemSCs.
In order to confirm real-time PCR results of Notch3 expression in IH tissue, immunofluorescence (IF) staining on proliferating and involuting IHs was performed. Notch3-positive cells were seen in hemangioma parenchyma and in perivascular cells surrounding vessel lumens. By contrast, there was stronger and more distinct staining of Notch3 around the lumens in the involuting IHs (Fig. 3) . Co-staining for Notch3 and CD31 clearly showed that Notch3 was not present on endothelial cells but on cells surrounding the endothelium (arrows). However, there was a small subpopulation of cells that stained for both CD31? and Notch3 (Fig. 3, arrowheads) . . When compared to placenta, both proliferating and involuting IHs had higher levels of gene transcripts for Notch1 (P \ 0.02 and P \ 0.003), Notch3 (P \ 0.025 and P \ 0.0005), and Notch4 (P \ 0.01 and P \ 0.0005), and involuting IHs showed higher expression levels of the Notch ligands Jagged-1 (P \ 0.0005) and Delta-like ligand 4 (Dll4) (P = 0.02) when compared to placenta. Both proliferating and involuting IHs had higher Notch4 (P \ 0.002 and P = 0.0001) and Dll4 (P \ 0.007 and P \ 0.005) mRNA expression when compared to skin. Furthermore, involuting IHs had higher Jagged-1 transcript levels (P \ 0.03) compared to skin. By contrast, Notch2 expression was significantly higher in placenta (P \ 0.03 and P \ 0.008) and skin (P \ 0.005 and P \ 0.005) compared to both proliferating and involuting IHs. * Statistical significance between IHs and placenta; # statistical significance between IHs and skin; $ statistical significance between proliferating and involuting IHs Notch1, Notch4, and Jagged-1 expression is associated with involuting IHs and HemECs HemECs had higher expression levels of Notch1, Notch4, Jagged-1, and Dll4 when compared to HemSCs, although gene expression levels of HemECs had some differences when compared to HDMEC. Namely, Notch1 levels were comparable, whereas Notch4 and Dll4 levels were lower than that found for HDMECs. Jagged-1 expression, on the other hand, was higher in HemECs than HDMECs. Importantly, the expression profile of Notch4 and Jagged-1 in HemSC and HemEC paralleled proliferating and involuting hemangiomas, respectively (Fig. 2) .
These data suggest that involuting hemangiomas become ''more endothelial'' in nature, based upon the Notch genes expressed. Thus, we speculate that HemSC differentiation into HemECs coincides with involution and changes in Notch gene expression.
To confirm PCR findings, protein expression was probed by immunostaining. Notch1 and Notch4 receptors and Jagged-1 were co-stained with CD31, a marker of endothelial cells. Immunofluorescence results show that the lumens of vessels are lined with CD31? endothelial cells (luminal ECs) that also expressed these Notch proteins (Figs. 4, 5, 6 ). Thus, they are expressed on endothelial cells. The lumens of proliferating specimens were less well-formed when compared to the involuting counterparts.
Discussion
Notch and Notch ligand expression in proliferating and involuting IHs are different and distinct from placenta and skin. Our data are consistent with Calicchio et al. [12] who showed that Notch4 and Jagged-1 expression were higher in proliferating IH when compared to placenta at the transcript level, although they did not analyze involuting IH. We here report a survey using both transcript and protein analysis on both proliferating and involuting IHs. In addition to the evaluation of Notch1, Notch4, and Jagged-1, we showed that Notch3 is primarily expressed by HemSC, with negligible levels in HemECs. This is consistent with previous studies, where Notch3 has not been reported to be expressed in endothelial cells, while its expression on mural cells has been well described [32, 33] . The Notch3 expression seen here in HemSCs and in IH tissue sections suggests that, in IH, vascular smooth muscle cells, which are seen in postnatal arteries and arterioles and are positive for Notch3, may arise from HemSCs, and maintenance of Notch3 expression in HemSCs may allow their differentiation into smooth muscle cells or pericytes rather than endothelial cells.
Our finding of a sub-population of CD31/Notch3 doubly positive cells is consistent with other evidence that HemSCs give rise to HemECs, and we speculate that the doubly positive CD31/Notch3 cells represent a transient intermediate between HemSC and HemEC-perhaps the hemangioma endothelial progenitor cell, or HemEPCs, previously described [18] -that will fully differentiate into EC and eventually lose Notch3 expression. An alternative to this model proposes that loss of Notch3 expression may be a result of HemSC acquisition of an endothelial cell fate and thus Notch3 may not be causative of this transition.
By contrast, the endothelial-associated Notch1, Notch4, and Jagged-1 are detected at higher expression levels in HemECs and are localized in the lumen-forming On the other hand, HemECs expressed endothelial-specific Notch genes: Notch1, Notch4, Jagged-1, and Delta-like ligand 4 (Dll4) at higher levels than HemSC, in a similar pattern to involuting and proliferating hemangiomas, where higher levels of Notch4 and Jagged-1 are seen in involuting IH. When compared to HDMECs, HemECs had similar transcript levels of Notch1, approximately 50% of Notch4 transcripts and twice the levels of Jagged-1 transcripts endothelium. Khan et al. [21] have shown that HemSCs can differentiate into HemECs. Therefore, our data imply that differentiation of HemSCs into HemECs is associated with the expression of endothelial Notch proteins (Notch1/ 4). We speculate that Notch may play a role in such differentiation/progression or, in contrast, Notch expression may be activated in response to signals that drive the differentiation of HemEC. Future studies will focus on the evaluation of Notch target gene expression, such as the Hes/Hey family of genes. In addition, there were scattered endothelial cells within the parenchyma that also expressed Notch1
Even though HemECs had higher levels of expression of the endothelial-associated Notch ligands Jagged-1 and Delta-like ligand 4 (Dll4) when compared to HemSCs, those levels were different from HDMECs. The level of Jagged-1 expression was almost double that of HDMECs. On the other hand, even though Dll4 levels were higher in HemECs when compared to HemSCs, they are all lower than Dll4 in HDMECs. Benedito et al. recently demonstrated that Jagged-1 and Dll4 have opposing effects on angiogenesis. More specifically, Jagged-1 acts as a potent pro-angiogenesis regulator and inhibits Dll4-Notch signaling. Dll-4 plays a role in selecting tip cells in sprouting and downregulates VEGF signaling [34] . The high level of Jagged-1 expression in both HemSCs and HemECs in IHs is consistent with the pro-angiogenesis milieu of IHs. This imbalance of Jagged-1 and Dll4 levels may contribute to dysregulated vessel formation in this vascular tumor. Proliferating hemangiomas are characterized as being hypercellular, but one also finds areas with and without lumen formation. In contrast, involuting hemangiomas have less cellular density, but are characterized by prominent well-formed vascular channels or lumens [3] . This finding implies that becoming ''more endothelial'' coincides with the end of the growth phase and the beginning of the involuting phase, and the appearance of well-organized lumenal structures. Notch3? perivascular cells may need to interact with HemECs to form vascular channels. This could in part explain the well-formed lumens and vascular channels in involuting hemangiomas. Recent reports have shown that Notch3 expression in mural cells can be induced by coculturing them with Jagged-1 expressing endothelial cell [35] .
Future studies will concentrate on elucidating mechanisms that may regulate the maintenance or loss of Notch3 expression in HemSCs and hemangioma-associated pericytes, in governing differentiation toward endothelial versus smooth muscle cell. In addition to fating cells toward a pericyte-smooth muscle cell fate, the role of Notch3 in maintaining pluripotency in HemSCs needs to be investigated.
